Abstract
Recent evidence shows that target low‐density lipoprotein cholesterol should be less than 100 mg/dl in patients with diabetes, and that even those with initially low levels benefit from pharmacologic therapy. Recent studies document that blood pressures lower than the previous target of 140/90 mmHg are beneficial, in addition to providing observational evidence against a lower threshold of benefit. Evidence that addresses the effect of blood glucose on macrovascular disease risk in patients with diabetes is reviewed. Finally, recommendations are made regarding systematic changes in healthcare delivery that will facilitate risk reduction strategies in diabetes.
Keywords: diabetes mellitus, blood pressure, hypertension, hyperlipidemia, glucose, lipids, cholesterol
Full Text
The Full Text of this article is available as a PDF (28.9 KB).
References
- 1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary artery disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229 [DOI] [PubMed] [Google Scholar]
- 2. Scandinavian Simvastatin Survival Study Group : Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389 [PubMed] [Google Scholar]
- 3. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E, for the CARE Investigators: Cardiovascular events and their reduction with pravastatin in diabetic and glucose‐intolerant myocardial infarction survivors with average cholesterol levels : Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation 1998; 98: 2513–2519 [DOI] [PubMed] [Google Scholar]
- 4. Heart Protection Collaborative Group : MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: A randomised placebo‐controlled trial. Lancet 2002; 360 [Google Scholar]
- 4a. Collins R, Armitage J, Parish S, Sleight P, Peto R: MRC/BHF heart protection study of cholesterol‐lowering in 5,963 people with diabetes: A randomized placebo‐controlled trial. Lancet 2003; 361: 2005–2016 [DOI] [PubMed] [Google Scholar]
- 5. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults : Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), J Am Med Assoc 2001; 285: 2486–2497 [DOI] [PubMed] [Google Scholar]
- 6. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. Br Med J 2000; 321 (7258): 412–419 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Du X, McNamee R, Cruickshank K: Stroke risk from multiple risk factors combined with hypertension: A primary care based case‐control study in a defined population of northwest England. Ann Epidemiol 2000; 10 (6): 380–388 [DOI] [PubMed] [Google Scholar]
- 8. Joint National Committee : The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157 (21): 2413–2446 [DOI] [PubMed] [Google Scholar]
- 9. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group: Effects of intensive blood‐pressure lowering and low‐dose aspirin in patients with hypertension : Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762 [DOI] [PubMed] [Google Scholar]
- 10. UK Prospective Diabetes Study Group : Tight blood pressure control and risk of macrovascular and microvascular disease in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703–713 [PMC free article] [PubMed] [Google Scholar]
- 11. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36 (3): 646–661 [DOI] [PubMed] [Google Scholar]
- 12. Heart Outcomes Prevention Evaluation Study Investigators : Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and the MICRO‐HOPE substudy. Lancet 2000; 355: 253–262 [PubMed] [Google Scholar]
- 13. Lonn E, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S, Moore‐Cox A, Bosch J, Riley WA, Teo KK, and the SECURE Investigators: Effects of ramipril and vitamin E on atherosclerosis : The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103 (7): 919–925 [DOI] [PubMed] [Google Scholar]
- 14. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe‐Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snappin S, for the LIFE study group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : A randomised trial against atenolol. Lancet 2002; 359: 1004–1010 [DOI] [PubMed] [Google Scholar]
- 15. Brenner BM, Cooper ME, DeZeeuw D, Keane WF, Mitch WE, Parving H‐H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869 [DOI] [PubMed] [Google Scholar]
- 16. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group : Reno‐protective effect of the angiotensin‐receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860 [DOI] [PubMed] [Google Scholar]
- 17. Parving H‐H, Lehnert H, Brochner‐Mortensen J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients with Type 2 Diabetes and Micro‐albuminuria Study Group : The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878 [DOI] [PubMed] [Google Scholar]
- 18. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium‐channel blocker vs. diuretic: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002. Dec 18; 288 (23): 2981–2997 [DOI] [PubMed] [Google Scholar]
- 19. Laasko M: Glycemic control and the risk of coronary artery disease in patients with NIDDM: The Finnish Studies. Ann Intern Med 1996; 124 (1 pt 2): 127–130 [DOI] [PubMed] [Google Scholar]
- 20. Haffner SM: Epidemiologic studies on the effects of hyperglycemia and improvement of glycemic control on macrovascular events in type 2 diabetes. Diabetes Care 1999; 22 (suppl 3): C54–56 [PubMed] [Google Scholar]
- 21. Turner RC, Millns H, Neil AW, Stratton IM, Manley SE, Matthews DR, Holman RR, for the United Kingdom Prospective Diabetes Study Group: Risk factors for coronary artery disease in non‐insulin dependent diabetes mellitus : UKPDS 23. Br Med J 1998; 316: 823–828 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. The Diabetes Control and Complications Trial Research Group : The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. N Engl J Med 1993; 329: 997 [DOI] [PubMed] [Google Scholar]
- 23. UKPDS Study Group : Effect of intensive blood‐glucose control with met‐formin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–865 [PubMed] [Google Scholar]
- 23a. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group : Intensive diabetes therapy and carotid intimamedia thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294–2303 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. ACE Diabetes Consensus Conference Panel , . P. D. P. (2001). ACE Consensus Conference on Guidelines for Glycemic Control, Washington, D. C., Endocrine Practice.
- 25. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen M‐R, Groop L: The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001; 44: 1148–1154 [DOI] [PubMed] [Google Scholar]
- 26. Khan MA, St. Peter JV, Xue JL: A prospective, randomized comparison of the metabolic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25: 708–711 [DOI] [PubMed] [Google Scholar]
- 27. Fujiwara T, Horikoshi H: Troglitazone and related compounds: Therapeutic potential beyond diabetes. Life Sci 2000; 67 (20): 2405–2416 [DOI] [PubMed] [Google Scholar]
- 28. Osende JI, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, Zaman A, Rodriguez OJ, Lev EI, Rauch U, Heflt G, Fallon JT, Crandall JP: Blood thrombogenicity in type 2 diabetes mellitus is associated with glycemic control. J Am Coll Cardiol 2001; 38: 1307–1312 [DOI] [PubMed] [Google Scholar]
- 29. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, Streicher P, Sieve‐Smith L, Tracy TM, Lang JE, McCullough P: Metformin reduces weight, centripetal obesity, insulin, leptin, and low‐density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 2001; 50 (7): 856–861 [DOI] [PubMed] [Google Scholar]
- 30. Mehnert H: Metformin, the rebirth of a biguanide: Mechanism of action and place in the prevention and treatment of insulin resistance. Exp Clin Endo‐crinol Diabetes 2001; 109 (suppl 2): S259–S264 [DOI] [PubMed] [Google Scholar]
- 31. Bruun JM, Pedersen SB, Richelsen B: Interleukin‐8 production in human adipose tissue. Inhibitory effects of anti‐diabetic compounds, the thiazo‐lidinedione ciglitazone and the biguanide metformin. Horm Metab Res 2000; 32 (11–12): 537–541 [DOI] [PubMed] [Google Scholar]
- 32. Meigs JB, Stafford RS: Cardiovascular disease prevention practices by U. S. physicians for patients with diabetes. J Gen Intern Med 2000; 15: 220–228 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. El‐Kabbi IM, Ziemer DC, Musey VC, Gallina DL, Bernard AM, Phillips LS: Diabetes in urban African‐Americans. IX. Provider adherence to management protocols. Diabetes Care 1997; 20: 698–703 [DOI] [PubMed] [Google Scholar]
- 34. Becker DM, Raqueno JV, Yook RM, Kral BG, Blumenthal RS, Moy TF, Bezirdijan PJ, Becker LC: Nurse‐mediated cholesterol management compared with enhanced primary care in siblings of individuals with premature coronary disease. Arch Intern Med 1998; 158: 1533–1539 [DOI] [PubMed] [Google Scholar]
- 35. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, Moskowitz MA: Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957–1963 [DOI] [PubMed] [Google Scholar]
- 36. Harris MI: Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000; 23 (6): 754–758 [DOI] [PubMed] [Google Scholar]
- 37. Phillips LS, Branch WT Jr, Cook CB, Doyle JP, El‐Kabbi IM, Gallina DL, Miller CD, Ziemer DC, Barnes CS: Clinical inertia. Ann Intern Med 2001; 135 (9): 825–834 [DOI] [PubMed] [Google Scholar]
- 38. Braunstein JB, Cheng A, Fakhry C, Nass CM, Vigilance C, Blumenthal RS: ABC's of cardiovascular disease risk management. Cardiol Rev 2001; 9 (2): 96–105 [DOI] [PubMed] [Google Scholar]